-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们将12个月目标价上调59美元至289美元,此举综合考虑了相对估值和现金流折现模型(DCF)分析。相对估值方面,我们对2027年预计EBITDA采用8.2倍的企业价值倍数,高于同行水平。我们认为,如果投资回报率高于同行(约高出17%),则该公司应享有溢价估值。基于此,我们得出每股价值275美元。同时,我们的DCF模型假设未来10年自由现金流年增长率为4.2%,之后为2.5%,得出每股价值303美元。我们将2026年每股收益预期上调14.86美元至27.85美元,并将2027年每股收益预期上调6.42美元至19.65美元。由于波斯湾原油产量受限,布伦特原油和WTI原油之间的价差(通常为每桶4美元,目前已达每桶8美元)有望在第二季度大幅提升,我们认为这种情况在未来几个季度也可能持续。VLO在3月份最大限度地提高了航空燃油产量,考虑到市场供应短缺,我们认为这是合理的。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.